Systematic Design and Comparison of Expanded Carrier Screening Panels

Kyle A. Beauchamp, Dale Muzzey, Kenny K. Wong, Gregory J. Hogan, Kambiz Karimi, Sophie I. Candille, Nikita Mehta, Rebecca Mar‐Heyming, Kristjan Eerik Kaseniit, Hyunseok P. Kang, Eric A. Evans, Judith D. Goldberg, Gabriel A. Lazarin, Imran S. Haque

Abstract

Purpose: The recent growth in pan-ethnic expanded carrier screening (ECS) has raised questions about how such panels might be designed and evaluated systematically. Design principles for ECS panels might improve clinical detection of at-risk couples and facilitate objective discussions of panel choice. Methods: Guided by medical-society statements, we propose a method for the design of ECS panels that aims to maximize the aggregate and per-disease sensitivity and specificity across a range of Mendelian disorders considered serious by a systematic classification scheme. We evaluated this method retrospectively using results from 474,644 de-identified carrier screens. We then constructed several idealized panels to highlight strengths and limitations of different ECS methodologies. Results: Based on modeled fetal risks for “severe” and “profound” diseases, a commercially available ECS panel (Counsyl) is expected to detect 183 affected conceptuses per 100,000 US births. A screen’s sensitivity is greatly impacted by two factors: (1) the methodology used (e.g., full-exon sequencing finds more affected conceptuses than targeted genotyping), and (2) the detection rate of the screen for diseases with high prevalence and complex molecular genetics (e.g., fragile X syndrome). Conclusion: The described approaches allow principled, quantitative evaluation of which diseases and methodologies are appropriate for pan-ethnic expanded carrier screening.

Introduction

Carrier screening is a vital tool for prospective parents to identify the risk of passing on recessive genetic disorders to their children. Historically, clinical guidelines recommended screening for a limited set of conditions based on a patient's reported ethnicity (e.g., Cystic Fibrosis or Tay-Sachs disease). However, the advent of Expanded Carrier Screening (ECS) has allowed for the simultaneous testing of hundreds of conditions regardless of ancestry.

Despite the proliferation of ECS, the industry lacks a consensus on panel composition. Many providers adopt a "more is better" philosophy, adding genes to panels without a rigorous assessment of their clinical utility. This study proposes a systematic, quantitative framework for designing ECS panels that prioritizes clinical impact—measured by the detection of affected pregnancies—over simple gene counts.

A Systematic Framework for Panel Design

The proposed methodology moves away from ad-hoc gene selection toward a four-step optimization process:

  1. Severity Classification: Not all genetic conditions carry the same clinical weight. The authors developed a rule-based scheme to categorize diseases as "mild," "moderate," "severe," or "profound." By focusing panel design on severe and profound conditions, clinicians can ensure that the screening provides actionable information for the most impactful disorders.
  2. Modeled Fetal Disease Risk (MFDR): While many panels are marketed based on "carrier frequency," this metric can be misleading. MFDR calculates the probability of an affected conceptus resulting from a random pairing in the population. This approach accounts for different inheritance patterns, such as autosomal recessive and X-linked conditions, providing a more accurate measure of a panel's potential to reduce disease burden.
  3. Sensitivity Optimization: The framework aims to maximize "aggregate sensitivity"—the fraction of total population risk a panel can detect. This is achieved by prioritizing high-incidence diseases and utilizing superior technology.
  4. Rigorous Variant Curation: To maintain high specificity, the authors implemented a "human-in-the-loop" pipeline. This ensures that the increased sensitivity of broad panels does not lead to an influx of false positives, which can cause unnecessary patient anxiety and invasive follow-up procedures.

The Impact of Methodology and Curation

The study analyzed a massive dataset of 474,644 de-identified carrier screens to compare different screening technologies. A key finding was the significant advantage of Next-Generation Sequencing (NGS) over traditional targeted genotyping. By sequencing the full exon rather than looking for specific, known mutations, NGS provided a 1.4x increase in the detection of affected fetuses for the same set of diseases. This benefit was particularly pronounced in underserved populations, such as Asian Americans, where traditional panels often miss population-specific mutations.

Furthermore, the research highlighted the importance of "special case" genes. Technically challenging genes—such as FMR1 (Fragile X syndrome), SMN1 (Spinal Muscular Atrophy), and CYP21A2 (Congenital Adrenal Hyperplasia)—account for 28.9% of the total fetal risk. Panels that omit these genes due to sequencing difficulty significantly compromise their clinical utility.

The study also addressed the bottleneck of variant interpretation. Automated tools like the Variant Effect Predictor (VEP) were found to be insufficient for clinical-grade screening; they either missed 65% of pathogenic variants or produced a 60% false-positive rate. The authors' manual, expert-led curation pipeline achieved 91.1% sensitivity and 99.7% specificity compared to ClinVar consensus, proving that expert review remains essential.

Results and Clinical Implications

The optimized ECS panel evaluated in this study is expected to detect 183 affected conceptuses per 100,000 US births. Beyond simple sequence variants, the inclusion of exon-level deletion calling (Copy Number Variants or CNVs) added approximately 4 affected fetuses per 100,000. While this 2% relative improvement may seem small, it is equivalent to the impact of adding 50 low-prevalence genes to a panel, demonstrating the value of technical depth over breadth.

One of the most critical metrics proposed is the per-disease Negative Predictive Value (NPV). The authors argue that a high NPV—giving parents true confidence in a negative result—is more valuable than a high gene count. A panel with 100 genes and 99% sensitivity is clinically superior to a 1,000-gene panel with only 10% sensitivity, even if the aggregate risk detected is identical.

Conclusion

As genomic technology continues to advance, the design of carrier screening panels must remain grounded in clinical evidence and quantitative modeling. By focusing on modeled fetal disease risk and high-sensitivity methodologies like NGS, the medical community can provide prospective parents with more accurate and meaningful information. This systematic approach ensures that ECS panels are evaluated not by the quantity of genes they include, but by their ability to identify at-risk pregnancies and improve reproductive outcomes.

Summary updated

Abstract

Abstract Purpose The recent growth in pan-ethnic expanded carrier screening (ECS) has raised questions about how such panels might be designed and evaluated systematically. Design principles for ECS panels might improve clinical detection of at-risk couples and facilitate objective discussions of panel choice. Methods Guided by medical-society statements, we propose a method for the design of ECS panels that aims to maximize the aggregate and per-disease sensitivity and specificity across a range of Mendelian disorders considered serious by a systematic classification scheme. We evaluated this method retrospectively using results from 474,644 de-identified carrier screens. We then constructed several idealized panels to highlight strengths and limitations of different ECS methodologies. Results Based on modeled fetal risks for “severe” and “profound” diseases, a commercially available ECS panel (Counsyl) is expected to detect 183 affected conceptuses per 100,000 US births. A screen’s sensitivity is greatly impacted by two factors: (1) the methodology used (e.g., full-exon sequencing finds more affected conceptuses than targeted genotyping), and (2) the detection rate of the screen for diseases with high prevalence and complex molecular genetics (e.g., fragile X syndrome). Conclusion The described approaches allow principled, quantitative evaluation of which diseases and methodologies are appropriate for pan-ethnic expanded carrier screening.
BibTeX
@inproceedings{beauchamp2017systematic,
  author = {Kyle A. Beauchamp and Dale Muzzey and Kenny K. Wong and Gregory J. Hogan and Kambiz Karimi and Sophie I. Candille and Nikita Mehta and Rebecca Mar‐Heyming and Kristjan Eerik Kaseniit and Hyunseok P. Kang and Eric A. Evans and Judith D. Goldberg and Gabriel A. Lazarin and Imran S. Haque},
  title = {{Systematic Design and Comparison of Expanded Carrier Screening Panels}},
  booktitle = {Genetics},
  year = {2017},
  doi = {10.1038/gim.2017.69},
}
Figure